Encorafenib

Red

Brand Name(s):Braftovi

Indication:Mutation-positive metastatic colorectal cancer in adults

Melanoma (unresectable or metastatic) – in adults

Rationale:1,2,3

Considered:Oct-18

Review Date:Jan-26

Comments:
NICE TA668 recommends encorafenib plus cetuximab, as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment only if the company provides it according to the commercial arrangements.